{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:34:08Z","timestamp":1791977648546,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.critrevonc.2006.01.001","type":"journal-article","created":{"date-parts":[[2006,7,26]],"date-time":"2006-07-26T06:54:57Z","timestamp":1153896897000},"page":"159-168","source":"Crossref","is-referenced-by-count":227,"title":["Oxaliplatin-related neurotoxicity: How and why?"],"prefix":"10.1016","volume":"59","author":[{"given":"Lara Maria","family":"Pasetto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Rosario","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Monfardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2006.01.001_bib1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1345\/aph.1E319","article-title":"Oxaliplatin-associated neuropathy: a review","volume":"39","author":"Cersosimo","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"2 Suppl. 5","key":"10.1016\/j.critrevonc.2006.01.001_bib2","first-page":"13","article-title":"Pharmacokinetics and safety profile of oxaliplatin","volume":"25","author":"Extra","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib3","first-page":"342","article-title":"Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model","volume":"46","author":"Holmes","year":"1998","journal-title":"Toxicol Sci"},{"issue":"5","key":"10.1016\/j.critrevonc.2006.01.001_bib4","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1152\/jn.2001.85.5.2293","article-title":"A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels","volume":"85","author":"Grolleau","year":"2001","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib5","first-page":"871","article-title":"Glutathione-related mechanisms in cellular resistance to anticancer drugs","volume":"12","author":"Zhang","year":"1998","journal-title":"Int J Oncol"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib6","first-page":"3577","article-title":"Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide","volume":"56","author":"Ban","year":"1996","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.critrevonc.2006.01.001_bib7","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","article-title":"Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomised, double-blind, placebo-controlled trial","volume":"20","author":"Cascinu","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2006.01.001_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(00)00667-1","article-title":"The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons","volume":"406","author":"Adelsberger","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"5 Suppl. 15","key":"10.1016\/j.critrevonc.2006.01.001_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","article-title":"Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures","volume":"29","author":"Gamelin","year":"2002","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2006.01.001_bib10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mus.10559","article-title":"Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy","volume":"29","author":"Lehky","year":"2004","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.critrevonc.2006.01.001_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mus.20340","article-title":"Oxaliplatin-induced neurotoxicity and the development of neuropathy","volume":"32","author":"Krishnan","year":"2005","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.critrevonc.2006.01.001_bib12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0304-3940(02)00651-1","article-title":"Failure to find evidence for association between voltage-gated sodium channel gene SCN2A variants and febrile seizures in humans","volume":"329","author":"Nakayama","year":"2002","journal-title":"Neurosci Lett"},{"issue":"6C","key":"10.1016\/j.critrevonc.2006.01.001_bib13","first-page":"4199","article-title":"Circulating nerve growth factor level changes during oxaliplatin treatment-induced neurotoxicity in the rat","volume":"22","author":"Cavaletti","year":"2002","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2006.01.001_bib14","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1054\/bjoc.1999.1026","article-title":"Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs","volume":"82","author":"Screnci","year":"2000","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2006.01.001_bib15","doi-asserted-by":"crossref","first-page":"354","DOI":"10.12968\/ijpn.2001.7.7.9020","article-title":"An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin","volume":"7","author":"Gent","year":"2001","journal-title":"Int J Palliat Nurs"},{"issue":"6","key":"10.1016\/j.critrevonc.2006.01.001_bib16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1179\/joc.2004.16.6.595","article-title":"Dysphonia as an unusual toxic event of oxaliplatin-based chemotherapy","volume":"16","author":"Berretta","year":"2004","journal-title":"J Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2006.01.001_bib17","first-page":"13","article-title":"Pharmacokinetics and safety profile of oxaliplatin","volume":"25","author":"Extra","year":"1998","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2006.01.001_bib18","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","article-title":"Acute oxaliplatin-induced peripheral nerve hyperexcitability","volume":"20","author":"Wilson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.critrevonc.2006.01.001_bib19","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2004.03.119","article-title":"Randomised multicenter phase II trial of bolus plus infusional fluorouracil\/leucovorin compared with fluorouracil\/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer","volume":"22","author":"Kemeny","year":"2004","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.critrevonc.2006.01.001_bib20","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.2003.07.941","article-title":"Therapeutic strategies for metastatic colorectal cancer: simultaneous, sequential, or specific?","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.critrevonc.2006.01.001_bib21","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil\u2013leucovorin compared with either therapy alone in patients with progressive colorectal cancer after CPT11 and fluorouracil\u2013leucovorin: interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.critrevonc.2006.01.001_bib22","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S0959-8049(99)00149-5","article-title":"Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR","volume":"35","author":"Maindrault-Goebel","year":"1999","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2006.01.001_bib23","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0959-8049(01)00068-5","article-title":"High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)","volume":"37","author":"Maindrault-Goebel","year":"2001","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2006.01.001_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","article-title":"FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study","volume":"22","author":"Tournigand","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib25","first-page":"169","article-title":"High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200","volume":"23","author":"Giantonio","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"16","key":"10.1016\/j.critrevonc.2006.01.001_bib26","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer","volume":"18","author":"de Gramont","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2006.01.001_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomised controlled trial of fluorouracil plus leucovorin, CPT11, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.critrevonc.2006.01.001_bib28","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","article-title":"XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer","volume":"22","author":"Cassidy","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib29","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1200\/jco.2005.23.16_suppl.3556","article-title":"A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer","volume":"23","author":"Fernando","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"23","key":"10.1016\/j.critrevonc.2006.01.001_bib30","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andre","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib31","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/jco.2005.23.16_suppl.3501","article-title":"Oxaliplatin\/5FU\/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years","volume":"23","author":"de Gramont","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib32","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/jco.2005.23.16_suppl.lba3500","article-title":"A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07","volume":"23","author":"Wolmark","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib33","first-page":"O-028","article-title":"Capecitabine plus oxaliplatin (XELOX) versus bolus FULV as adjuvant therapy for patients with stage III colon cancer: preliminary safety findings from a randomised phase III trial","author":"Schmoll","year":"2005","journal-title":"The World Congress of Gastrointestinal Cancer"},{"issue":"May (1)","key":"10.1016\/j.critrevonc.2006.01.001_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3816\/CCC.2002.n.011","article-title":"Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer","volume":"2","author":"Lersch","year":"2002","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib35","first-page":"609","article-title":"Oxaliplatin induced neuropathy: could gabapentin be the answer?","volume":"19","author":"Mariani","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2006.01.001_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-2002-19594","article-title":"Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study","volume":"127","author":"Eckel","year":"2002","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib37","article-title":"A phase III double blinded, placebo controlled. Randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: a North Central Cancer Treatment Group Study","volume":"23","author":"Wong","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2006.01.001_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1023\/A:1011184609963","article-title":"Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy","volume":"12","author":"Penz","year":"2001","journal-title":"Ann Oncol"},{"issue":"6 Suppl. 18","key":"10.1016\/j.critrevonc.2006.01.001_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.seminoncol.2003.11.018","article-title":"Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design","volume":"30","author":"Samuels","year":"2003","journal-title":"Semin Oncol"},{"issue":"16","key":"10.1016\/j.critrevonc.2006.01.001_bib40","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","article-title":"Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomised, double-blind, placebo-controlled trial","volume":"20","author":"Cascinu","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.critrevonc.2006.01.001_bib41","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/annonc\/mdi222","article-title":"High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil\/leucovorin for elderly patients with advanced colorectal cancer","volume":"16","author":"Mattioli","year":"2005","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2006.01.001_bib42","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3816\/CCC.2005.s.006","article-title":"Clinical management of oxaliplatin-associated neurotoxicity","volume":"5","author":"Grothey","year":"2005","journal-title":"Clin Colorectal Cancer"},{"issue":"4 Suppl. 15","key":"10.1016\/j.critrevonc.2006.01.001_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0093-7754(03)00399-3","article-title":"Oxaliplatin-safety profile: neurotoxicity","volume":"30","author":"Grothey","year":"2003","journal-title":"Semin Oncol"},{"issue":"15","key":"10.1016\/j.critrevonc.2006.01.001_bib44","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.2002.99.502","article-title":"Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid","volume":"20","author":"Gedlicka","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.critrevonc.2006.01.001_bib45","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","article-title":"Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer","volume":"10","author":"Gamelin","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.critrevonc.2006.01.001_bib46","first-page":"8654","article-title":"Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer","volume":"61","author":"Park","year":"2001","journal-title":"Cancer Res"},{"issue":"14S","key":"10.1016\/j.critrevonc.2006.01.001_bib47","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/jco.2004.22.14_suppl.3627","article-title":"Genomic profiling as predictor of toxicity in patients with advanced colorectal cancer treated with platinum-based chemotherapy","volume":"22","author":"Park","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.critrevonc.2006.01.001_bib48","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/S0959-8049(01)00300-8","article-title":"Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat","volume":"37","author":"Cavaletti","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2006.01.001_bib49","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/annonc\/mdf254","article-title":"Exacerbation of oxaliplatin neurosensory toxicity following surgery","volume":"13","author":"Gornet","year":"2002","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2006.01.001_bib50","first-page":"342","article-title":"Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model","volume":"46","author":"Holmes","year":"1998","journal-title":"Toxicol Sci"},{"issue":"10","key":"10.1016\/j.critrevonc.2006.01.001_bib51","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1023\/A:1008213732429","article-title":"Oxaliplatin: a review of preclinical and clinical studies","volume":"9","author":"Raymond","year":"1998","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.critrevonc.2006.01.001_bib52","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/(SICI)1099-081X(199705)18:4<347::AID-BDD23>3.0.CO;2-O","article-title":"Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin","volume":"18","author":"Figg","year":"1997","journal-title":"Biopharm Drug Disp"},{"issue":"5","key":"10.1016\/j.critrevonc.2006.01.001_bib53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s002800050683","article-title":"Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity","volume":"40","author":"Aamdal","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.critrevonc.2006.01.001_bib54","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00001813-199708000-00001","article-title":"A phase II and pharmacokinetic study of enloplatin in patients with platinum refractory advanced ovarian carcinoma","volume":"8","author":"Kudelka","year":"1997","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.critrevonc.2006.01.001_bib55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s002800050484","article-title":"A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N,N\u2032) platinum in patients with refractory advanced breast cancer","volume":"38","author":"Theriault","year":"1996","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280600014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084280600014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,20]],"date-time":"2019-04-20T07:59:04Z","timestamp":1555747144000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084280600014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S104084280600014X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2006.01.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}